Head-to-head · WeighScore
Eloria vs No BS RX
By GLP-1 ScorecardUpdated
Score comparison
No BS RX has the higher recorded score — 82.8/100 to 65.6/100.
No BS RX grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. No BS RX publishes separate prices for standard compounded, low-dose and brand-name programs.
Before you choose
Before comparing the headline prices, the Eloria review and the No BS RX review set out the plan length, renewal date and extra fees behind each semaglutide figure in the table below, and the semaglutide cost page compares published rates across the field. A lower starting price can still mean a larger bill once a longer commitment or a separate membership is added.
If neither one fits, Eloria vs Sesame Care and EmbraceRX vs No BS RX compare each of them with another graded program, and the list of alternatives to Eloria ranks the programs closest to Eloria on price, features and score. Those pages, like every entry in the review directory, use the same six graded factors, so the scores carry across.
Of the sellers that pay us a commission, the Belle Health review covers one graded close to these two, at 73.8/100. That relationship never changes a grade, and the review lists what we could not verify.
We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.
Factor by factor
These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.
The numbers
Swipe or scroll to compare both providers.
| Metric | Eloria | No BS RX |
|---|---|---|
| WeighScore | 65.6/100 | 82.8/100 |
| Grade | C | B− |
| Site position | #234 | #23 |
| Semaglutide | $179/mo (starting dose, plus a separate fee, compounded) | $149/mo advertised for standard compounded injection; low-dose priced separately |
| Tirzepatide | Not disclosed | $225/mo advertised for standard compounded injection; low-dose priced separately |
| Coverage | Coverage not published | Confirm program availability for your state |
| Brand-name access | Yes | Yes |
| Oral / sublingual | Yes | Yes |
Strengths
- Compounded GLP-1 injections from $179/mo and oral dissolving tablets from $249/mo, with no membership or hidden fees
- Also offers brand Wegovy (pill or injection) on a $99/mo membership plus medication cost
- Board-certified providers (via Arora Health & Aesthetics) and US-licensed pharmacies
- HSA/FSA accepted, free shipping on every order, and 24/7 support
- Full published compliance suite (Terms, Privacy, Refund, Shipping, Physician Code of Conduct, Consent to Telehealth)
What to consider
- Compounded medications are not FDA-approved - not brand Ozempic, Zepbound, or Mounjaro
- State availability varies and is not published - only where providers are licensed and pharmacies can dispense
- The compounding pharmacy partner is not named (US-licensed pharmacies only)
- No LegitScript certification displayed
- Brand Wegovy uses a separate $99/mo membership-plus-medication-cost model
Strengths
- Displays monthly and prepaid amounts by program
- Advertises consultation, medication, shipping and messaging in the compounded plans
- Lists branded Ozempic and Zepbound separately
What to consider
- The $115 headline applies to low-dose programs
- Plans renew automatically at the then-current rate
- Cancellation generally stops future billing without refunding the current period
Featured provider
CoreAge Rx
CoreAge Rx scores 89.5/100 (B+). Advertises pricing across doses with no membership fee, but starting-price displays and FAQ payment/refund promises need to be reconciled with the selected plan and refund policy.
Commercial relationships affect this placement. The score comparison above is separate.
Prices and terms can change; confirm them with the provider. Our factor scores may reflect earlier assessments; see our methodology. Not medical advice; see our disclosure.